Recent events
Recent events tied to this brand in public sources.
Back to profile26 entries · Page 1 of 2
2026
AbbVie completes acquisition of Apogee Therapeutics
AbbVie completed its acquisition of Apogee Therapeutics, as reported in the release dated Oct. 30.
2026
US FDA approves AbbVie's drug for Parkinson's disease
The US Food and Drug Administration approved AbbVie's drug for Parkinson's disease, as reported by Reuters.
2026
AbbVie reports third-quarter 2026 results
AbbVie reported third-quarter 2026 revenue of $17.404 billion, up 10.3% year over year, and adjusted EPS of $3.82.
2026
AbbVie raises full-year adjusted EPS guidance
AbbVie raised its full-year adjusted EPS guidance from $13.76–$13.96 to $13.95–$13.99.
2022
FDA approves Skyrizi for active psoriatic arthritis in adults
The FDA approved AbbVie’s risankizumab-rzaa (Skyrizi) for treating adults with active psoriatic arthritis, expanding its indication beyond plaque psoriasis. The article does not state the approval date.
2021
FDA approves AbbVie’s Qulipta for migraine prevention
The U.S. Food and Drug Administration approved AbbVie’s Qulipta for the preventive treatment of episodic migraine in adults.
2021
BTL and AbbVie settle patent dispute
BTL announced that it had resolved its patent infringement claims against AbbVie related to BTL's muscle stimulation technology. Under the settlement, AbbVie will pay BTL an undisclosed amount, and pending litigation between the parties will be dismissed.
2021
FDA approves Botox label expansion for adult upper limb spasticity
The FDA approved a Botox label expansion to include eight additional muscles and ultrasound use for treatment of upper limb spasticity in adults.
2021
FDA approves Dalvance for pediatric infections
The FDA approved AbbVie's Dalvance for treatment of acute bacterial skin and skin structure infections in pediatric patients from birth, according to the report.
2021
AbbVie to acquire TeneoOne
AbbVie exercised its option to acquire TeneoOne, the Teneobio affiliate developing the cancer drug TNB-383B, for an undisclosed sum.
2021
AbbVie and Caraway collaborate on Parkinson’s disease therapeutic
AbbVie and Caraway Therapeutics entered into a collaboration agreement to develop and commercialize a small molecule targeting TMEM175, a target involved in Parkinson’s disease and other neurodegenerative conditions.
2021
AbbVie files second suit against Alvotech
AbbVie brought a second action against Alvotech hf. in the Northern District of Illinois, alleging patent infringement in connection with Alvotech’s proposed HUMIRA biosimilar.
2021
Alvotech files suit against AbbVie over Humira patents
Alvotech USA and Alvotech hf filed a declaratory-judgment complaint against AbbVie in the Eastern District of Virginia, alleging that patents in AbbVie’s Humira portfolio were invalid or unenforceable and seeking declaratory judgments of non-infringement and invalidity.
2021
Capsida Biotherapeutics secures $140 million in capital
Capsida Biotherapeutics emerged from stealth mode with $140 million in startup capital, including a $50 million Series A commitment from Versant Ventures and Westlake Village BioPartners and $90 million in upfront and equity investment capital from its collaboration agreement with AbbVie.
2021
Capsida and AbbVie announce gene therapy collaboration
Capsida announced a multi-year strategic collaboration and option agreement with AbbVie to develop targeted gene therapies for three central nervous system disease targets. The agreement includes $80 million in upfront cash and a $10 million equity investment for Capsida.
2021
Pharmaron announces agreement to acquire the ABL site
Pharmaron announced a definitive agreement to acquire Allergan Biologics Limited’s biomanufacturing site in Liverpool from AbbVie for US$118.7 million in cash. The transaction was expected to close in the second quarter of 2021, subject to customary closing conditions.
2021
FDA approves Humira for pediatric ulcerative colitis
The U.S. Food and Drug Administration approved Humira (adalimumab) to treat moderately to severely active ulcerative colitis in pediatric patients aged 5 and older.
2020
I-Mab and AbbVie announce global strategic partnership
I-Mab announced a global development and commercialization partnership with AbbVie for lemzoparlimab and potential related bispecific antibodies, with payments and royalties described in the announcement.
2020
AbbVie and I-Mab enter global licensing agreement for lemzoparlimab
AbbVie and I-Mab entered a licensing agreement under which AbbVie will pay an upfront amount and develop and sell I-Mab's CD47 antibody lemzoparlimab globally.
2020
FDA approves AbbVie treatment for fibroid-related heavy menstrual bleeding
The U.S. Food and Drug Administration approved AbbVie Inc.'s oral treatment for managing heavy menstrual bleeding associated with fibroids in premenopausal women. The label includes a boxed warning about increased risks of blood clots, heart attacks and strokes, and the agency warned of increased bone-loss risk with use for more than 24 months.